Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06800768

The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

This study aims to investigate the value of 68Ga-FAPI PET/CT in detecting recurrent and metastatic lesions in patients with thyroid cancer after surgery.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

Shanghai, Shanghai Municipality, 200001, China

Location status: Recruiting

Location contact

Qinyu Li

CONTACT

[email protected]

15221971915

About this study

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-FAPI PET/CT when recurrence or metastasis is suspected. The imaging response measurements will be compared with follow-up results or histopathological findings as the gold standard.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with thyroid cancer who have undergone surgery and are suspected of recurrence or metastasis during clinical evaluation.
  • Signed and dated informed consent form.
  • Commitment to comply with research procedures and co-operation in the implementation of the full research process.
  • Aged 18-80 years old.

Exclusion criteria

  • Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
  • Intestinal perforation, complete intestinal obstruction.
  • Pregnant women and women who may be pregnant, women who are breastfeeding.
  • Non-compliant person.

Treatment and study plan

Primary outcomes

  1. Diagnosis of recurrent or metastatic thyroid cancer

    Time frame: Within 1 week after enrollment

    The value of 68Ga-FAPI PET/CT in detecting recurrent and metastatic lesions in patients with thyroid cancer after surgery

Secondary outcomes

  1. Standardized uptake value(SUV)

    Time frame: Within 1 week after enrollment

    SUV of 68Ga-FAPI uptake on PET/CT images for tumor lesions

  2. Disease free survival

    Time frame: 3 years

    Disease free survival

Study contacts

Contact information is provided by the study sponsor or research team.

Jiajia Hu

CONTACT

[email protected]

13524945287

Sponsors and collaborators

Lead sponsor

Ruijin Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Jan 30, 2025
Registry last updated
Jan 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.